6 December 2017Big Pharma

LSPN Europe 2017: Lack of consistency on doctrine of equivalents

The UK Supreme Court’s approach in Actavis v Eli Lilly brought the country closer to harmonisation with other European nations, but there’s still not a wholly consistent view on the doctrine of equivalents across Europe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

Squires refuses to resurrect HydraFacial patent review

Litigator from Brown Rudnick moves firms to chair practice

INTA 2026: In-house tips on what to do in London

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

LSPN Europe 2017: Lack of consistency on doctrine of equivalents

More on this story

Editor's picks

Editor's picks

More features